insulin glargine U200

**Insulin glargine U200** is a concentrated, long-acting recombinant human insulin analog designed for once-daily subcutaneous administration in the management of diabetes mellitus. The U200 formulation contains 200 units of insulin glargine per milliliter, which allows delivery of larger basal insulin doses in a reduced injection volume compared to standard U100 preparations. Insulin glargine acts by binding the insulin receptor, leading to increased glucose uptake in skeletal muscle and adipose tissue and inhibition of hepatic glucose production. Its unique amino acid substitutions cause it to precipitate in subcutaneous tissue after injection, resulting in slow, prolonged absorption and a relatively stable, peakless 24-hour activity profile. The principal indication for insulin glargine U200 is to improve glycemic control in adults with type 1 and type 2 diabetes mellitus, especially when higher total daily insulin requirements necessitate a more concentrated formulation.

Brand names

Toujeo Max SoloStar

Other names

insulin glargine U200